PERSONAL INFORMATION
Name: Zhang Xiao
Gender: Male
Title: phD
Position: Associated professor
CONTACT INFORMATION
Email: zhangxiao@cqmu.edu.cn
Address: No. 1, Medical College Road,, Yuzhong District, Chongqing City, PRC
Phone: +86-13926470727
EDUCATION EXPERIENCE
Sep 2005 - Jun 2009 Shandong University, Weihai, China
Major: Biological Science
Degree: Bachelor of Science
2. Sep 2009 - Jun 2012 Xiamen University, Xiamen, China
Major: Microbiology
Degree: Master of Science
3. Sep 2012 - Dec 2015 Xiamen University, Xiamen, China
Major: Biochemistry and Molecular Biology
Degree: Ph.D of Science
WORKING EXPERIENCE
1. Date of employment: Aug 2022-to date
Position Title: Associate professor
Company Name: Chongqing Medical University
2. Date of employment: Nov 2018-Jul 2022
Position Title: Associate research fellow
Company Name: Sun Yat-Sen University Cancer Center
3. Date of employment: Apr 2016-Nov 2018
Position Title: Postdoctor
Company Name: Sun Yat-Sen University Cancer Center
RESEARCH INTERESTS
1. Prophylactic Vaccines and Neutralizing Antibodies against Viral Infection
2. Small Molecule Targeted Drugs Based on Structure of Viral Capsid
3. Innovative Adjuvants
HONOUR & AWARDS
1. The First National Postdoctoral Innovation and Entrepreneurship Competition Biomedical Excellence Award (Ranked First)
2. The 5th National Society of Virology Young Scholars Academic Seminar, Second Prize for Excellent Poster (Ranked First)
3. The 2023 Annual Conference of the Chinese Antibody Society, First Prize for Excellent Poster (Ranked First)
PUBLICATIONS
(1) Ling Zhong (#), Wanlin Zhang (#), Hong liu (#), Xinyu Zhang (#), Zeyu Yang, Zhenfu Wen, Ling Chen, Haolin Chen, Yanran Luo, Yanhong Chen, Qisheng Feng, Mu-Sheng Zeng, Qinjian Zhao, Lixin Liu, Claude Krummenacher (*), Yi-Xin Zeng (*), Yongming Chen (*), Miao Xu (*), Xiao Zhang (*). A trivalent nanovaccine targeting key entry glycoproteins elicits high quality neutralizing antibodies against EBV infection. Nature Communications. 2023. (Under Review)
(2) Qian Wu (#), Ling Zhong (#), Dongmei Wei (#), Wanlin Zhang (#), Junping Hong (#), Yinfeng Kang, Kaiyun Chen, Yang Huang, Qingbing Zheng, Miao Xu, Mu-Sheng Zeng, Yi-Xin Zeng, Ningshao Xia, Qinjian Zhao, Claude Krummenacher (*), Yixin Chen (*), Xiao Zhang (*). Neutralizing antibodies against EBV gp42 show potent in vivo protection and define novel epitopes. Emerging Microbes & Infections. 2023.08.04. 12(2):2245920.
(3) Junping Hong (#), Ling Zhong (#), Liqin Liu (#), Qian Wu (#), Wanlin Zhang (#), Kaiyun Chen (#), Xiang Zhou, Hui Sun, Dongmei Wei, Xinyu zhang, Yinfeng Kang, Yang Huang, Junyu Chen, Guosong Wang, Yan zhou, Yanhong Chen, Qisheng Feng, Hai Yu, Shaowei Li, Mu-Sheng Zeng, Yi-Xin Zeng, Miao Xu (*), Qingbing Zheng (*), Yixin Chen (*), Xiao Zhang (*), Ningshao Xia (*). A cocktail of anti-gp42 and anti-gHgL antibodies provide synergistic neutralization and protection against EBV infection. Cell Reports Medicine. 2023. (Revision Submitted)
(4) Ling Zhong (#), Qinjian Zhao, Xiao Zhang (*). Unmasking the enigma: Epstein-Barr virus as a primary trigger in multiple sclerosis. Journal of Autoimmune Disorders. 2023.6.14. 9(2):31.
(5) Ling Zhong (#), Wanlin Zhang (#), Claude Krummenacher (#), Yixin Chen, Qingbing Zheng, Qinjian Zhao, Mu-Sheng Zeng, Ningshao Xia, Yi-Xin Zeng, Miao Xu (*), Xiao Zhang (*). Targeting herpesvirus entry complex and fusogen glycoproteins with prophylactic and therapeutic agents. Trends in Microbiology. 2023.03.24, 31 (8):788-804.
(6) Ling Zhong (#), Claude Krummenacher (#), Wanlin Zhang, Junping Hong, Qisheng Feng, Yixin Chen, Qinjian Zhao, Mu-Sheng Zeng, Yi-Xin Zeng, Miao Xu (*), Xiao Zhang (*). Urgency and Necessity of Epstein-Barr Virus Prophylactic Vaccines. npj Vaccines, 2022.12.9, 7 (1):159.
(7) Ling Zhong, Claude Krummenacher, Wanlin Zhang, Junping Hong, Qisheng Feng, Qinjian Zhao, Yixin Chen, Mu-Sheng Zeng, Yi-Xin Zeng, Miao Xu (*), Xiao Zhang (*). A high-throughput neutralizing assay for antibodies and sera evaluation against Epstein-Barr virus. Virology Journal, 2022.11.23, 19 (1):196.
(8) Xiao Zhang (#)(*), Junping Hong (#), Ling Zhong (#), Qian Wu (#), Shanshan Zhang (#), Qianying Zhu (#), Haiwen Chen, Dongmei Wei, Rui Li, Wanlin Zhang, Xinyu Zhang, Guosong Wang, Xiang Zhou, Junyu Chen, Yinfeng Kang, Zhenghui Zha, Xiaobing Duan, Yang Huang, Cong Sun, Xiangwei Kong, Yan Zhou, Yanhong Chen, Xiaoping Ye, Qisheng Feng, Shaowei Li, Tong Xiang, Song Gao, Mu-Sheng Zeng, Qingbing Zheng (*), Yixin Chen (*), Yi-Xin Zeng (*), Ningshao Xia (*), Miao Xu (*). Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. Proceedings of the National Academy of Sciences of the USA, 2022.08.02, 119 (32):e2202371119.
(9) Junping Hong (#), Dongmei Wei (#), Ling Zhong (#), Qian Wu (#), Kaiyun Chen, Wanlin Zhang, Yanbo Yang, Junyu Chen, Ningshao Xia, Xiao Zhang (*), Yixin Chen (*). Glycoprotein B antibodies completely neutralize EBV infection of B cells. Frontiers in Immunology, 2022.05.27, 13:920467.
(10) Kong Xiangwei (#), Zhang Xiao (#), Bu Guolong (#), Xu Huiqing, Kang Yinfeng, Sun Cong, Zhu Qianying, Ma Runbo, Liu Zheng, Zeng Yi-Xin, Zeng Mu-Sheng (*), Hu Zhulong (*).Vesicular stomatitis virus-based Epstein-barr virus vaccines elicit strong protective immune responses. Journal of Virology, 2022.05.11, 96(9):e0033622.
(11) Junping Hong (#), Ling Zhong (#), Qingbing Zheng (#), Qian Wu (#), Zhenghui Zha, Dongmei Wei, Haiwen Chen, Wanlin Zhang, Shanshan Zhang, Yang Huang, Kaiyun Chen, Junyu Chen, Shaowei Li, Mu-Sheng Zeng, Yi-Xin Zeng, Ningshao Xia, Xiao Zhang (*), Miao Xu (*), Yixin Chen (*). A neutralizing antibody targeting gH provides potent protection against EBV challenge in vivo. Journal of Virology. 2022.03.29, 96(8):e00075-22.
(12) Junping Hong (#), Dongmei Wei (#), Qian Wu (#), Ling Zhong, Kaiyun Chen, Yang Huang, Wanlin Zhang, Junyu Chen, Ningshao Xia, Xiao Zhang (*), Yixin Chen (*). Antibody generation and immunogenicity analysis of EBV gp42 N-terminal region. Viruses, 2021.11.28, 13:2380.
(13) Haiwen Chen (#), Ling Zhong (#), Wanlin Zhang (#), Shanshan Zhang, Junping Hong, Xiang Zhou, Xinyu Zhang, Qisheng Feng, Yixin Chen, Yi-Xin Zeng, Miao Xu, Claude Krummenacher (*), Xiao Zhang (*). Dose-dependent outcome of EBV infection of humanized mice based on green raji unit (GRU) doses. Viruses, 2021.10.29, 13:2184.
(14) Xiang Zhou (#), Su-Mei Cao (#), Yong-Lin Cai (#), Xiao Zhang (#), Shanshan Zhang, Guo-Fei Feng, Yufeng Chen, Qi-Sheng Feng, Yijun Chen, Ellen T. Chang, Zhonghua Liu, Hans-Olov Adami, Jianjun Liu, Weimin Ye, Zhe Zhang (*), Yi-Xin Zeng (*), and Miao Xu (*). A comprehensive risk score for effective risk stratification and screening of nasopharyngeal carcinoma. Nature Communications, 2021.08.31, 12:5189.
(15) Kang Yinfeng (#), Zhang Xiao (#), Yu Xiaohui (#), Zheng Qingbing, Liu Zhe, Li Jiangping, Sun Cong, Kong Xiangwei, Zhu Qianying, Chen Haiwen, Huang Yang, Xu Miao, Zhong Qian, Zeng Yi-Xin (*), Zeng Mu-Sheng (*). Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection. Nano Letters, 2021.03.08, 21(6):2476-2486.
(16) Chen Haiwen (#), Zhang Xiao (#), Zhang Shanshan, Duan Xiaobing, Xiang Tong, Zhou Xiang, Zhang Wanlin, Zhang Xinyu, Feng Qisheng, Kang Yinfeng, Li Jiangping, Deng Lan, Wang Liang, Lv Xing, Zeng Musheng, Zeng Yixin (*), Xu Miao (*). T cell epitope screening of Epstein-Barr virus fusion protein gB. Journal of Virology, 2021.03.03, 95(10):e00081-21.
(17) Li Zhihai (#), Zhang Xiao (#), Dong Lili, Pang Jingjing, Xu Miao, Zhong Qian, Zeng Mu-Sheng (*), Yu Xuekui (*). CryoEM structure of the tegumented capsid of Epstein-Barr virus. Cell Research, 2020.07.03, 30(10):873-884.
(18) Zhang Xiao (#), Zhao Bingchun (#), Ding Mingmei, Song Shuo, Kang Yinfeng, Yu Yang, Xu Miao, Xiang Tong, Gao Ling, Feng Qisheng, Zhao Qinjian (*), Zeng Mu-Sheng (*), Claude Krummenacher, Zeng Yi-Xin (*). A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics, 2020.08.27, 10(13):5704-5718.
(19) Wang Kaihang (#), Zhou Lizhi (#), Zhang Xiao (#), Song Cuiling, Chen Tingting, Li Jiajia, Zheng Minghua, Wang Yingbin, Zheng Qingbing, Zheng Zizheng, Yu Hai, Wu Ting, Gu Ying, Zhang Jun, Zhao Qinjian (*), Li Shaowei (*), Xia Ningshao (*). Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A. Antiviral Research, 2019.02.23, 164:154-161.
(20) Zhao Bingchun (#), Zhang Xiao (#), Krummenacher Claude, Song Shuo, Gao Ling, Zhang Haojiong, Xu Miao, Feng Lin, Feng Qisheng, Zeng Musheng, Xu Yuting, Zeng Yixin (*). Immunization with Fc-based recombinant Epstein-barr virus gp350 elicits potent neutralizing humoral immune response in a balb/c mice model. Frontiers in Immunology, 2018.05.01, 9:932.
(21) Zhang Xiao (#), Wei Minxi, Sun Guang, Wang Xin, Li Min, Lin Zhijie, Li Zhongyi, Li Yufang, Fang Mujin, Zhang Jun, Li Shaowei, Xia Ningshao (*), Zhao Qinjian (*). Real-time stability of a hepatitis E vaccine (Hecolin (R)) demonstrated with potency assays and multifaceted physiochemical methods. Vaccine, 2016.10.25, 34(48):5871-5877.
(22) Zhang Xiao (#), Wang Kaihang (#), Lin Qingshan (#), Zheng Minghua, Li Qiong, Li Tingting, Hong Qiyang, Zheng Qingbing, Yu Hai (*), Gu Ying, Li Shaowei (*), Xia Ningshao (*). A shared N-terminal hydrophobic tail for the formation of nanoparticulates. Nanomedicine, 2016.08.08, 11(17):2289-303.
(23) Zhang Xiao (#), Li Shaowei, Modis Yorgo, Li Zhihai, Zhang Jun, Xia Ningshao (*), Zhao Qinjian (*). Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Reviews in Medical Virology, 2015.12.17, 26(2):115-128.
(24) Zhang Xiao (#), Xin Lu, Li Shaowei, Fang Mujin, Zhang Jun, Xia Ningshao (*), Zhao Qinjian (*). Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Human Vaccines & Immunotherapeutics，2015.05.27, 11(5):1277-1292.
(25) Zhang Xiao (#), Wei Minxi (#), Pan Huirong, Lin Zhijie, Wang Kaihang, Weng Zusen, Zhu Yibin, Xin Lu, Zhang Jun, Li Shaowei, Xia Ningshao (*), Zhao Qinjian (*). Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin (R). Vaccine, 2014.06.02, 32(32):4039-50.
(26) Wei Minxi (#), Zhang Xiao (#), Yu Hai, Tang Zi-Min, Wang Kaihang, Li Zhongyi, Zheng Zizheng, Li Shaowei, Zhang Jun, Xia Ningshao (*), Zhao Qinjian (*). Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine, 2014.03.22, 32(24):2859-2865.
